文献速递慢性肾脏病遗传性与小管间质肾病

帕瑞肽长效释放剂治疗常染色体显性多囊肾或肝病伴严重肝受累的随机临床试验

Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2020-08-25

该1年双盲随机试验将48例严重多囊肝病患者按2:1分配至帕瑞肽长效释放剂组或安慰剂组,主要终点为总肝体积变化。结果显示帕瑞肽组年化总肝体积和总肾体积变化率显著降低,但高血糖和糖尿病发生率显著增高。

要点

  • 帕瑞肽长效释放剂可减缓严重多囊肝病患者的总肝体积和总肾体积增长速率。
  • 帕瑞肽组高血糖(79% vs 27%)和新发糖尿病(59% vs 7%)发生率显著高于安慰剂组。
  • 两组eGFR变化相似,帕瑞肽未影响肾功能下降。

核心结论

  • 帕瑞肽长效释放剂减缓了总肝体积和总肾体积的增长速率,但未影响GFR下降。
  • 帕瑞肽组高血糖和糖尿病不良事件发生率更高。

研究设计与样本

  • 1年双盲随机对照试验,48例严重多囊肝病患者按2:1分配至帕瑞肽长效释放剂组或安慰剂组。
  • 41例完成总肝体积测量(帕瑞肽组29例,安慰剂组12例)。

主要发现

  • 帕瑞肽组年化身高校正总肝体积变化为-99±189 ml/m(-3%±7%),安慰剂组为136±117 ml/m(6%±7%),P<0.001。
  • 帕瑞肽组总肾体积变化为-12±34 ml/m(-1%±4%),安慰剂组为21±21 ml/m(4%±5%),P=0.05。
  • 两组eGFR变化相似。
  • 帕瑞肽组高血糖发生26/33(79%),安慰剂组4/15(27%),P<0.001。
  • 基线无糖尿病的47例中,帕瑞肽组19/32(59%)发生糖尿病,安慰剂组1/15(7%),P=0.001。

临床怎么用

  • 帕瑞肽长效释放剂可用于减缓严重多囊肝病患者肝、肾体积增长,但需密切监测血糖和糖尿病发生。

局限性

  • 样本量较小(完成总肝体积测量者41例),可能影响结果的精确性。
  • 研究仅纳入严重多囊肝病患者,结论外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: We assessed safety and efficacy of another somatostatin receptor analog, pasireotide long-acting release, in severe polycystic liver disease and autosomal dominant polycystic kidney disease. Pasireotide long-acting release, with its broader binding profile and higher affinity to known somatostatin receptors, has potential for greater efficacy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Individuals with severe polycystic liver disease were assigned in a 2:1 ratio in a 1-year, double-blind, randomized trial to receive pasireotide long-acting release or placebo. Primary outcome was change in total liver volume; secondary outcomes were change in total kidney volume, eGFR, and quality of life. RESULTS: Of 48 subjects randomized, 41 completed total liver volume measurements (n=29 pasireotide long-acting release and n=12 placebo). From baseline, there were -99±189 ml/m absolute and -3%±7% change in annualized change in height-adjusted total liver volume (from 2582±1381 to 2479±1317 ml/m) in the pasireotide long-acting release group compared with 136±117 ml/m absolute and 6%±7% increase (from 2387±759 to 2533±770 ml/m) in placebo (P<0.001 for both). Total kidney volumes decreased by -12±34 ml/m and -1%±4% in pasireotide long-acting release compared with 21±21 ml/m and 4%±5% increase in the placebo group (P=0.05 for both). Changes in eGFR were similar between groups. Among the n=48 randomized, adverse events included hyperglycemia (26 of 33 [79%] in pasireotide long-acting release versus four of 15 [27%] in the placebo group; P<0.001), and among the 47 without diabetes at baseline, 19 of 32 (59%) in the pasireotide long-acting release group versus one of 15 (7%) in the placebo group developed diabetes (P=0.001). CONCLUSIONS: Another somatostatin analog, pasireotide long-acting release, slowed progressive increase in both total liver volume/total kidney volume growth rates without affecting GFR decline. Participants experienced higher frequency of adverse events (hyperglycemia and diabetes). CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Pasireotide LAR in Severe Polycystic Liver Disease, NCT01670110 PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2020_08_28_CJN13661119.mp3.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Hogan MC, Chamberlin JA, Vaughan LE, et al. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial. Clin J Am Soc Nephrol. 2020. PMID: 32843370. doi:10.2215/CJN.13661119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。